The stock price of Chemomab Therapeutics Ltd ADR (NASDAQ: CMMB) has jumped by 17.83 compared to previous close of 1.57. Despite this, the company has seen a gain of 28.92% in its stock price over the last five trading days. investorplace.com reported 2024-08-21 that Chemomab Therapeutics (NASDAQ: CMMB ) just reported results for the second quarter of 2024. Chemomab Therapeutics reported earnings per share of -26 cents.
Is It Worth Investing in Chemomab Therapeutics Ltd ADR (NASDAQ: CMMB) Right Now?
Moreover, the 36-month beta value for CMMB is 0.60. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CMMB is 12.62M and currently, short sellers hold a 1.29% of that float. On November 13, 2024, CMMB’s average trading volume was 221.58K shares.
CMMB’s Market Performance
The stock of Chemomab Therapeutics Ltd ADR (CMMB) has seen a 28.92% increase in the past week, with a 54.17% rise in the past month, and a 77.88% gain in the past quarter. The volatility ratio for the week is 10.98%, and the volatility levels for the past 30 days are at 10.60% for CMMB. The simple moving average for the past 20 days is 24.94% for CMMB’s stock, with a 69.75% simple moving average for the past 200 days.
Analysts’ Opinion of CMMB
Many brokerage firms have already submitted their reports for CMMB stocks, with Maxim Group repeating the rating for CMMB by listing it as a “Buy.” The predicted price for CMMB in the upcoming period, according to Maxim Group is $4 based on the research report published on May 13, 2024 of the current year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see CMMB reach a price target of $6. The rating they have provided for CMMB stocks is “Outperform” according to the report published on May 06th, 2024.
ROTH MKM gave a rating of “Buy” to CMMB, setting the target price at $7 in the report published on December 19th of the previous year.
CMMB Trading at 16.69% from the 50-Day Moving Average
After a stumble in the market that brought CMMB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.45% of loss for the given period.
Volatility was left at 10.60%, however, over the last 30 days, the volatility rate increased by 10.98%, as shares surge +41.22% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.80% lower at present.
During the last 5 trading sessions, CMMB rose by +29.37%, which changed the moving average for the period of 200-days by +242.59% in comparison to the 20-day moving average, which settled at $1.4805. In addition, Chemomab Therapeutics Ltd ADR saw 262.75% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CMMB starting from OrbiMed Israel Partners Limite, who proposed sale 500,000 shares at the price of $2.03 back on Sep 12 ’24. After this action, OrbiMed Israel Partners Limite now owns shares of Chemomab Therapeutics Ltd ADR, valued at $1,015,000 using the latest closing price.
Stock Fundamentals for CMMB
The total capital return value is set at -1.57. Equity return is now at value -94.14, with -69.37 for asset returns.
Based on Chemomab Therapeutics Ltd ADR (CMMB), the company’s capital structure generated -0.34 points at debt to capital in total, while cash flow to debt ratio is standing at 3.55. The debt to equity ratio resting at -0.25. The interest coverage ratio of the stock is -10764.38.
Currently, EBITDA for the company is -25.39 million with net debt to EBITDA at 0.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.12.
Conclusion
To wrap up, the performance of Chemomab Therapeutics Ltd ADR (CMMB) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
